## **Product** Data Sheet

## Rufinamide-d2

Cat. No.: HY-A0042S

CAS No.: 1129491-38-8 Molecular Formula:  $C_{10}H_6D_2F_2N_4O$ 

Molecular Weight: 240.21

Target: Isotope-Labeled Compounds

Pathway: Others

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

## **BIOLOGICAL ACTIVITY**

Description	Rufinamide- $d_2$ (CGP 33101- $d_2$ ) is the deuterium labeled Rufinamide. Rufinamide (E 2080) is a new antiepileptic agent that differs structurally from other antiepileptic drugs and is approved as adjunctive therapy for Lennox-Gastaut syndrome (LGS).
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **REFERENCES**

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
- [2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
- [3]. Suter MR, Kirschmann G, Laedermann CJ, Rufinamide attenuates mechanical allodynia in a model of neuropathic pain in the mouse and stabilizes voltage-gated sodium channel inactivated state. Anesthesiology. 2013 Jan;118(1):160-72.
- [4]. White HS, Franklin MR, Kupferberg HJ, The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models. Epilepsia. 2008 Jul;49(7):1213-20.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech@MedChemExpress.com$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA